Vuity Availability: What Providers and Prescribers Need to Know in 2026

Since its FDA approval in October 2021, Vuity (pilocarpine hydrochloride ophthalmic solution 1.25%) has carved out a unique niche in presbyopia management. As the first and only FDA-approved ophthalmic drop specifically indicated for presbyopia at launch, it opened an entirely new pharmacologic category for eye care providers. However, patient access continues to be a friction point — and as the prescribing provider, you are often the one fielding calls from frustrated patients who can't fill their prescription.

This guide provides a clinical and logistical overview of Vuity availability in 2026, along with practical strategies for ensuring your patients can actually access the medications you prescribe.

Current Supply Status: No Official FDA Shortage

As of 2026, Vuity is not listed on the FDA's drug shortage database. Manufacturing and distribution by Allergan (AbbVie) are ongoing. The supply chain disruptions are not at the manufacturer or wholesale level — they arise from downstream pharmacy stocking decisions.

Unlike shortage medications that require emergency protocols or 340B workarounds, Vuity availability issues are primarily a distribution and market adoption challenge. The drug is available through standard pharmaceutical distributors; pharmacies simply choose not to stock it in many cases.

Why Pharmacies Don't Routinely Stock Vuity

Understanding the pharmacy economics helps explain the pattern your patients are experiencing:

No insurance reimbursement driver: Most commercial insurance, Medicare Part D, and Medicare Advantage plans do not cover Vuity. When a drug isn't on any formulary, pharmacies receive no DUR-driven reimbursement signal to stock it. Pharmacies stock to demand, and without prior authorization queues generating demand signals, Vuity stays off the automatic reorder lists.

Low initial volume: Presbyopia drops are a niche prescriber market. Adoption has been concentrated among ophthalmology and optometry practices that proactively counsel patients on the option. Most PCPs are not prescribing it, limiting volume at general pharmacies.

Ophthalmic specialty stocking: Eye drops — especially specialty ophthalmic drops — are often handled differently in pharmacy distribution. Some chain pharmacies route ophthalmic specialty products through specialty channels, requiring additional steps for fulfillment.

Key 2025–2026 Developments Affecting Your Prescribing Decisions

1. Generic Pilocarpine 1.25% (August 2025)

A generic pilocarpine hydrochloride 1.25% ophthalmic solution launched commercially in August 2025. When prescribing, consider writing for pilocarpine 1.25% ophthalmic solution (dispense as written or generic permitted) to give patients and pharmacies more flexibility. The generic may be more available at some locations and comes at a lower cost — an important consideration since Vuity is a cash-pay medication.

2. Competitive Landscape: Qlosi and Vizz

Two additional presbyopia drops entered the US market in 2025:

Qlosi (pilocarpine 0.4%, Orasis Pharmaceuticals): FDA-approved October 2023, commercially available April 2025. Preservative-free. Lower pilocarpine concentration with potentially fewer side effects. Available primarily through mail-order.

Vizz (aceclidine 1.44%, LENZ Therapeutics): FDA-approved July 2025, commercially available October 2025. First aceclidine-based presbyopia drop. Once-daily, lasts up to 10 hours, preservative-free. Supported by three phase 3 trials (CLARITY 1, 2, and 3).

When Vuity is unavailable, these are clinically defensible alternatives to offer patients rather than having them go untreated. Patient selection (degree of presbyopia, side effect tolerance, lifestyle needs) should guide choice.

Clinical Pearls: Optimizing Vuity Prescribing for Access

Write for the generic: Unless the patient specifically needs brand-name Vuity, writing 'pilocarpine 1.25% ophthalmic solution' or 'Vuity (pilocarpine 1.25%), substitution permitted' gives pharmacies flexibility.

Identify preferred pharmacy partners: Work with 2-3 local pharmacies that reliably stock Vuity. Make this a standard handout in your office so staff can direct patients immediately.

Consider dispensing in-office: Ophthalmology and optometry practices can often dispense Vuity directly. This improves patient adherence and eliminates the pharmacy access barrier for the initial fill.

Counsel on samples: Allergan representatives may provide sample vials. Patients who receive a sample before committing to a purchase show higher adherence rates, and sampling helps identify non-responders early.

Recommend medfinder for patient-side searching: Direct patients to medfinder.com/providers to find pharmacies near them that currently have Vuity in stock. This reduces callbacks to your office.

Retinal Screening Before Prescribing: A Reminder

As with all miotics, the Vuity package insert recommends a retinal examination in all patients prior to initiating therapy. Patients with preexisting retinal disease are at elevated risk for retinal detachment and retinal tear. This remains an important clinical gatekeeping step, especially as the category becomes more mainstream and non-eye-care providers may begin prescribing.

Helping Patients Navigate Access: Provider Resources

medfinder offers a provider-specific platform at medfinder.com/providers where you can direct patients. Our service calls pharmacies near the patient's location to identify who can fill their Vuity prescription — reducing the burden on your staff and improving prescription fill rates for your patients.